Survival and desferrioxamine in thalassaemia major.
- 10 April 1982
- Vol. 284 (6322), 1081-1084
- https://doi.org/10.1136/bmj.284.6322.1081
Abstract
A small randomised trial and observation of all patients homozygous for beta-thalassaemia in Britain born in or before 1963 indicated that those patients who had received average weekly doses of more than 4 g of desferrioxamine over the previous few years were less likely to die in the near future than were patients of similar ages who had received less, or no, desferrioxamine.Keywords
This publication has 14 references indexed in Scilit:
- PREVENTION OF IRON LOADING IN TRANSFUSION-DEPENDENT THALASSÆMIAThe Lancet, 1978
- Echocardiographic abnormalities in patients with transfusion-dependent anemia and secondary myocardial iron depositionAmerican Journal Of Medicine, 1978
- Cardiac arrhythmias in thalassaemia major: evaluation of chelation treatment using ambulatory monitoring.BMJ, 1978
- Continuous Subcutaneous Administration of Deferoxamine in Patients with Iron OverloadNew England Journal of Medicine, 1977
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977
- SUBCUTANEOUS INFUSION AND INTRAMUSCULAR INJECTION OF DESFERRIOXAMINE IN PATIENTS WITH TRANSFUSIONAL IRON OVERLOADThe Lancet, 1976
- Reassessment of the Use of Desferrioxamine B in Iron OverloadNew England Journal of Medicine, 1976
- A controlled trial of long-term chelation therapy in homozygous beta-thalassemia.1976
- LONG‐TERM DESFERRIOXAMINE THERAPY IN THALASSEMIAAnnals of the New York Academy of Sciences, 1974
- Long-term Chelation Therapy in Thalassaemia Major: Effect on Liver Iron Concentration, Liver Histology, and Clinical ProgressBMJ, 1974